摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要:
A self-cleaning humidity sensor based on Mg2+/Na+-doped TiO2 nanofiber mats is provided. Examples show the response and recovery characteristic curves for ten circles with the RH changing from 11% to 95%. The nanofibers are manufactured by mixing together a metal salt comprising titanium, a magnesium compound, a sodium compound, and a high molecular weight material to form a mixture, electrospinning the mixture to form composite nanofibers, and calcining the composite nanofibers to yield a TiO2 nanofiber material doped with magnesium and sodium.
摘要翻译:提供了基于Mg2 + / Na +掺杂的TiO2纳米纤维垫的自洁湿度传感器。 示例显示了10个圆的响应和恢复特性曲线,RH从11%变化到95%。 纳米纤维通过将包含钛,镁化合物,钠化合物和高分子量材料的金属盐混合在一起而制备,以形成混合物,静电纺混合物以形成复合纳米纤维,并煅烧复合纳米纤维以产生TiO 2纳米纤维 掺杂镁和钠的材料。
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要:
Techniques to perform fast motion estimation are described. An apparatus may comprise a motion estimator operative to receive as input a current frame and a reference frame from a digital video sequence. The motion estimator may generate and output a motion vector. The motion vector may represent a change in position between a current block of the current frame and a matching reference block of the reference frame. The motion estimator may utilize an enhanced block matching technique to perform block matching based on stationary and spatially proximate blocks. Other embodiments are described and claimed.
摘要:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要:
Techniques and tools are described for parameterization, signaling and use of in-loop filtering control information for interlaced video frames in video acceleration. For example, for a macroblock of an interlaced video frame, a decoder parameterizes in-loop filtering decisions as filter control information for video acceleration. The control information indicates filtering control decisions for external edges and internal edges of luma blocks and chroma blocks of the macroblock. The decoder makes the control information available to a video accelerator. The video accelerator retrieves the in-loop filtering control information. For a macroblock of an interlaced video frame, the video accelerator then performs in-loop filtering based at least in part on the control information.